37,490 Hinge Health Inc. $HNGE Shares Sold by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC decreased its stake in shares of Hinge Health Inc. (NYSE:HNGE) by 26.9% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 101,660 shares of the company’s stock after selling 37,490 shares during the period. Hinge Health accounts for about 2.7% of Lisanti Capital Growth LLC’s portfolio, making the stock its 2nd largest holding. Lisanti Capital Growth LLC owned 0.13% of Hinge Health worth $9,885,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of HNGE. IFP Advisors Inc lifted its position in Hinge Health by 140.0% during the second quarter. IFP Advisors Inc now owns 324 shares of the company’s stock worth $27,000 after acquiring an additional 189 shares during the last quarter. Nykredit A S acquired a new position in shares of Hinge Health in the second quarter valued at approximately $29,000. SBI Securities Co. Ltd. grew its position in shares of Hinge Health by 39.5% in the third quarter. SBI Securities Co. Ltd. now owns 364 shares of the company’s stock valued at $35,000 after purchasing an additional 103 shares during the last quarter. Sterling Capital Management LLC increased its stake in shares of Hinge Health by 899.3% during the third quarter. Sterling Capital Management LLC now owns 1,469 shares of the company’s stock worth $143,000 after purchasing an additional 1,322 shares during the period. Finally, Allspring Global Investments Holdings LLC bought a new position in shares of Hinge Health during the third quarter worth approximately $204,000.

Insider Activity

In related news, CFO James Budge sold 55,561 shares of the company’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $89.45, for a total transaction of $4,969,931.45. Following the completion of the sale, the chief financial officer directly owned 349,062 shares in the company, valued at $31,223,595.90. This represents a 13.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President James Pursley sold 33,000 shares of the stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $88.05, for a total transaction of $2,905,650.00. Following the completion of the transaction, the president directly owned 706,235 shares of the company’s stock, valued at $62,183,991.75. This trade represents a 4.46% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 1,024,581 shares of company stock valued at $95,632,761. 18.92% of the stock is owned by insiders.

Hinge Health Trading Down 1.3%

Shares of HNGE stock opened at $121.67 on Thursday. The stock has a market cap of $9.82 billion, a P/E ratio of 66.97, a price-to-earnings-growth ratio of 1.74 and a beta of 1.19. The stock has a 50 day simple moving average of $102.75 and a 200 day simple moving average of $70.04. Hinge Health Inc. has a 1 year low of $30.08 and a 1 year high of $126.40.

Hinge Health (NYSE:HNGE) last issued its earnings results on Monday, November 2nd. The company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.27 by $0.44. The company had revenue of $234.97 million during the quarter. Hinge Health had a net margin of 21.02% and a return on equity of 66.96%. Hinge Health’s quarterly revenue was up 52.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.02) earnings per share. Analysts forecast that Hinge Health Inc. will post 1.56 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Barclays boosted their price target on Hinge Health from $100.00 to $110.00 and gave the company an “overweight” rating in a research note on Monday, October 12th. Evercore reiterated an “outperform” rating and set a $105.00 price objective on shares of Hinge Health in a research report on Wednesday, August 5th. Needham & Company LLC lifted their target price on Hinge Health from $115.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, November 3rd. Truist Financial lifted their target price on Hinge Health from $112.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, November 3rd. Finally, KeyCorp boosted their target price on shares of Hinge Health from $125.00 to $140.00 and gave the company an “overweight” rating in a research report on Friday, October 16th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Hinge Health currently has an average rating of “Buy” and an average target price of $118.93.

Hinge Health Profile

Hinge Health is a digital health company focused on musculoskeletal care, including support for people with back, joint and muscle pain. Its services are designed to help members manage conditions through personalized, technology-enabled care. The company’s offerings include app-based exercise therapy, education and behavioral support, along with access to clinical care teams. Hinge Health also uses wearable motion sensors in some programs to guide and track exercises. Founded in 2015, Hinge Health primarily provides its services through employers and health plans.